LM
KZR

Luminus Management’s Kezar Life Sciences KZR Stock Holding History

Luminus Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,900
Closed -$1.34M – 56
2020
Q2 		$1.34M Buy
+25,900
New +$1.31M 0.17% 33

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Luminus Management's KZR Position: Q3 2020 in Review

Luminus Management sold out of Kezar Life Sciences (KZR) in Q3 2020, closing a stake of 25,900 shares — an estimated $1.34M sold.

Luminus Management first reported a position in KZR in Q2 2020 and held it in 1 quarter. The position peaked at $1.34M in Q2 2020. 78 funds tracked by Wall St. Rank hold KZR as of Q3 2020.

  • Luminus Management reported no remaining Kezar Life Sciences position as of Q3 2020 after selling out during the quarter.
  • Luminus Management sold 25,900 Kezar Life Sciences shares in Q3 2020, an estimated $1.34M.
  • Luminus Management first reported a position in Kezar Life Sciences in Q2 2020 and held it in 1 quarter.
  • Luminus Management's Kezar Life Sciences position peaked at $1.34M in Q2 2020.
  • 78 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2020.

Based on Luminus Management's 13F filing for Q3 2020, filed 16 Nov 2020.